Akums introduces Tamsulosin + Tadalafil capsule — to the Indian market, ET HealthWorld


New Delhi: Akums Drugs and Pharmaceuticals Limited introduces the Tamsulosin + Tadalafil capsule — to the Indian market. The combined therapy, delivered in a fixed dose combination within a hard gelatin capsule, marks an important achievement for the company. The formulation of Tamsulosin 0.4/0.4mg + Tadalafil 2.5/5mg, has been approved by the Drug Controller General of India (DCGI).

Tamsulosin is a selective alpha1A-adrenergic receptor antagonist. The effects of tamsulosin are targeted at the smooth muscle receptors of the prostate and urethra. Blocking this receptor relaxes the smooth muscle of the bladder and urethra to improve urine flow. It is primarily used when an enlarged prostate impedes normal urine flow and bladder emptying.

In tandem, the mechanism of action for Tadalafil centres on the inhibition of PDE5, a crucial enzyme located in the vascular smooth muscle cells of the corpus cavernosum. By impeding cGMP hydrolysis, Tadalafil promotes cGMP accumulation and the relaxation of vascular smooth muscle, facilitating the development of a physiologically-induced erection, contingent upon sexual stimulation.

Sanjeev Jain, Jt Managing Director, Akums Drugs & Pharmaceuticals Ltd emphasised, “This innovative combination therapy not only offers a more convenient treatment option but also represents a significant leap forward in our pursuit of enhancing patient outcomes.”

Sandeep Jain, Jt Managing Director, Akums Drugs & Pharmaceuticals Ltd, added, “Our dedicated team’s relentless efforts have culminated in the development of a product that not only meets rigorous regulatory standards but also aims to significantly improve the quality of life for patients.”

Each hard gelatin capsule is composed of Tamsulosin Hydrochloride IP at 0.4/0.4mg (in its extended-release form) and Tadalafil IP at 2.5/5mg (as a film-coated tablet).

Focusing on the urology segment, the Tamsulosin + Tadalafil capsule boasts several key features. Demonstrating significant improvements in BPH & Erectile Dysfunction Index, the combination significantly improves Total, Voiding, and Storage IPSS (International Prostate Symptom Score), thereby offering a better efficacy on LUTS relief.

  • Published On Sep 15, 2023 at 05:24 PM IST

Join the community of 2M+ industry professionals

Subscribe to our newsletter to get latest insights & analysis.

Download ETHealthworld App

  • Get Realtime updates
  • Save your favourite articles


Scan to download App


Leave a Reply

Your email address will not be published. Required fields are marked *